~~<i id='06CB68D93C'><strike id='06CB68D93C'><tt id='06CB68D93C'><pre id='06CB68D93C'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：fashion 2025-09-28 17:42:39 Page View：763

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： STAT Summit: Ending the crisis of Black deaths in the U.S.
Next article： Anesthesiologist group: stop taking Ozempic before surgery

comprehensive

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Roivant's CEO is a star, but biotech's black hole persists

MollyFerguson/STATRoivantSciences’MattGlinemightbethisyear’sbestbiopharmaCEO,andotherthoughtsaboutMo

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

J&J lung cancer data amount to new salvo against AstraZeneca

TheJohnson&JohnsonboothatESMO2023.AndrewJoseph/STATMADRID—Acompetitionhasbeenbrewingbetweentwoph